Smoking, air pollution and MS

Hear the latest data on the association between smoking and an increased risk of MS. There are several interesting new data.

Adverse events with fatal outcome

Sporadic cases of fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. In this MEDtalk Trygve Holmøy present a study based on European Medicines Agency database of suspected adverse reactions related to medicinal products in the European Economic Area (EudraVigilance), for fatal adverse events associated with treatment with alemtuzumab. Trygve Holmøy and colleagues identified nine cases with a probable and one case with a possible causal relationship between alemtuzumab treatment and a fatal adverse event.

Highlights from ECTRIMS

Melinda Magyari, Head of the Danish MS Registry, gives in this MEDtalk some of her highlights from the ECTRIMS Congress.

A larger decrease in total costs was observed in patients with MS who received their first disease modifying therapies early, which could potentially be explained by a slower disease progression leading to maintained work capacity.

Galina Zheleznyakova have dentified a number of different sncRNAs where further research may pave the way for identification of informative biomarkers and possible treatment targets. In this MEdtalk she present the result from the study.

The MS brain lesion atlas (msatlas.dk) is a user-friendly interactive web interface developed to address the current challenges of understanding mechanisms driving the fate of progressive MS on lesion basis. Click and hear more about how this first MS Atlas be a new basis for treatment development.